A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

Background: Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumour. However, rates of discordance vary considerabl...

Full description

Bibliographic Details
Main Authors: Chan, Arlene, Morey, A., Brown, B., Hastrich, D., Willsher, P., Ingram, D.
Format: Journal Article
Published: 2012
Online Access:http://hdl.handle.net/20.500.11937/25823